Ameliorative effect of Ferula Asafoetida oleo-gum-resin (Asafin) against cisplatin induced functional dyspepsia condition

Pharmacological Research - Natural Products Pub Date : 2024-11-01 DOI:10.1016/j.prenap.2024.100117

Svenia P. Jose , Ratheesh M , Sheethal S , Sony Rajan , Krishnakumar IM , Sandya S

{"title":"Ameliorative effect of Ferula Asafoetida oleo-gum-resin (Asafin) against cisplatin induced functional dyspepsia condition","authors":"Svenia P. Jose , Ratheesh M , Sheethal S , Sony Rajan , Krishnakumar IM , Sandya S","doi":"10.1016/j.prenap.2024.100117","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Functional dyspepsia (FD), affecting over 30 % of the global population, manifests with symptoms like fullness, bloating, epigastric pain, early satiety, and gastric motility issues. In the current study, we investigated the efficacy and mechanism of action of a water-soluble powder formulation of Ferula Asafoetida oleo-gum-resin (Asafin) in an animal model of Cisplatin-induced (CP) FD.</div></div><div><h3>Methods</h3><div>The animals were divided into four groups: Group I - Normal, Group II - Cisplatin control, Group III - Cisplatin + Standard drug, and Group IV - Cisplatin + Asafin. Various parameters including body weight, food intake, hematological markers, biochemical markers, and histopathology were analyzed during and after a 30-day study period.</div></div><div><h3>Results</h3><div>It was observed that CP-treated animals exhibited a marked reduction in food intake and body weight, which significantly improved or reversed when treated with Asafin. Further analysis of gut peptide hormones (Leptin, Ghrelin, GLP-1) and their gene expressions confirmed delayed gastric emptying and impaired gastric motility in CP rats. However, co-administration of Asafin with CP showed a significant improvement in these markers, indicating the normalization of the symptoms. These results were also consistent with the observed gene expressions of appetite-regulating GI peptide hormones CCK, POMC, MTL, NPY, and CART, which returned to normal levels. Histopathology results further supported the significant improvement provided by Asafin in CP rats</div></div><div><h3>Conclusions</h3><div>Our findings suggest that Asafin may mitigate FD risk by modulating the gut-brain axis via gut peptide hormones and neurotransmitters.</div></div>","PeriodicalId":101014,"journal":{"name":"Pharmacological Research - Natural Products","volume":"5 ","pages":"Article 100117"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacological Research - Natural Products","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950199724001058","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Functional dyspepsia (FD), affecting over 30 % of the global population, manifests with symptoms like fullness, bloating, epigastric pain, early satiety, and gastric motility issues. In the current study, we investigated the efficacy and mechanism of action of a water-soluble powder formulation of Ferula Asafoetida oleo-gum-resin (Asafin) in an animal model of Cisplatin-induced (CP) FD.

Methods

The animals were divided into four groups: Group I - Normal, Group II - Cisplatin control, Group III - Cisplatin + Standard drug, and Group IV - Cisplatin + Asafin. Various parameters including body weight, food intake, hematological markers, biochemical markers, and histopathology were analyzed during and after a 30-day study period.

Results

It was observed that CP-treated animals exhibited a marked reduction in food intake and body weight, which significantly improved or reversed when treated with Asafin. Further analysis of gut peptide hormones (Leptin, Ghrelin, GLP-1) and their gene expressions confirmed delayed gastric emptying and impaired gastric motility in CP rats. However, co-administration of Asafin with CP showed a significant improvement in these markers, indicating the normalization of the symptoms. These results were also consistent with the observed gene expressions of appetite-regulating GI peptide hormones CCK, POMC, MTL, NPY, and CART, which returned to normal levels. Histopathology results further supported the significant improvement provided by Asafin in CP rats

Conclusions

Our findings suggest that Asafin may mitigate FD risk by modulating the gut-brain axis via gut peptide hormones and neurotransmitters.

查看原文本刊更多论文

阿魏油胶树脂（Asafin）对顺铂引起的功能性消化不良的改善作用

背景功能性消化不良（FD）影响着全球30%以上的人口，表现为饱胀、腹胀、上腹痛、早饱和胃蠕动问题等症状。在本研究中，我们研究了阿魏油胶树脂水溶性粉剂（Asafin）在顺铂诱导（CP）FD 动物模型中的疗效和作用机制：I组为正常组，II组为顺铂对照组，III组为顺铂+标准药物组，IV组为顺铂+Asafin组。在 30 天的研究期间和之后，对体重、食物摄入量、血液标记物、生化标记物和组织病理学等各种参数进行了分析。结果表明，CP 治疗动物的食物摄入量和体重明显减少，而使用阿沙芬治疗后，情况明显好转或逆转。对肠道肽类激素（Leptin、Ghrelin、GLP-1）及其基因表达的进一步分析证实，CP 大鼠的胃排空延迟，胃蠕动受损。然而，阿沙芬与氯化石蜡联合给药后，这些指标均有明显改善，表明症状趋于正常。这些结果也与观察到的食欲调节消化道肽类激素CCK、POMC、MTL、NPY和CART的基因表达相一致，它们都恢复到了正常水平。结论我们的研究结果表明，阿萨芬可以通过肠道肽类激素和神经递质调节肠道-大脑轴，从而降低FD风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacological Research - Natural Products

自引率

0.00%

发文量